MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, UTHR made $3,182,700K in revenue. $1,334,700K in net income. Net profit margin of 41.94%.

Income Overview

Revenue
$3,182,700K
Net Income
$1,334,700K
Net Profit Margin
41.94%
EPS
$27.86
Unit: Thousand (K) dollars
Revenue Breakdown
    • Tyvaso DPI
    • Nebulized Tyvaso
    • Remodulin
    • Others
Revenue Breakdown
    • US
    • Non Us

Income Statement
2025-12-31
Total revenues
3,182,700
Cost of sales
384,400
Research and development
550,000
Selling, general, and administrative
755,800
Total operating expenses
1,690,200
Operating income
1,492,500
Interest income
192,000
Interest expense
19,500
Other income (expense), net
48,900
Total other income, net
221,400
Income before income taxes
1,713,900
Income tax expense
379,200
Net income
1,334,700
Basic EPS
30.13
Diluted EPS
27.86
Basic Average Shares
44,300,000
Diluted Average Shares
47,900,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Tyvaso DPI$1,292,500K Nebulized Tyvaso$585,700K Remodulin$526,800K Orenitram$496,900K Unituxin$226,800K Adcirca$30,000K Product And ServiceOther$24,000K Total revenues$3,182,700K Interest income$192,000K Other income(expense), net$48,900K Operating income$1,492,500K Total other income,net$221,400K Total operatingexpenses$1,690,200K Interest expense$19,500K Income before incometaxes$1,713,900K Selling, general, andadministrative$755,800K Research and development$550,000K Cost of sales$384,400K Net income$1,334,700K Income tax expense$379,200K

UNITED THERAPEUTICS Corp (UTHR)

UNITED THERAPEUTICS Corp (UTHR)